MDS Nordion
RELATED CONTENT
July 9, 2010 – Lantheus Medical Imaging Inc. announced this week that it has signed a new manufacturing and supply agreement with MDS Nordion to purchase molybdenum-99 (Mo-99), the parent isotope of technetium-99m (Tc-99m).
July 09, 2010 
March 16, 2010 - Physicians took new steps toward understanding what patient type would benefit most from Yttrium-90 radioembolization treatment for hepatocellular carcinoma (HCC).
March 16, 2010
February 9, 2010 - About 22,600 cases of primary liver cancer are diagnosed each year in the U.S. and one million annually worldwide, reports the American Cancer Society.
February 09, 2010
August 4, 2009 - MDS Nordion, a leading provider of medical isotopes and radiopharmaceuticals, has submitted a proposal to Canada’s Expert Review Panel on Medical Isotope and Technetium-99m (Tc-99m) Generator Production, stating the best answer to the shortage of medical radioisotopes is the completion and bringing into service of the MAPLE project.
August 04, 2009
June 16, 2009 - MDS Nordion, a leading global provider of medical isotopes and radiopharmaceuticals used in molecular medicine, and the Karpov Institute of Physical Chemistry in Moscow, Russia, have agreed to study the feasibility of the Karpov Institute providing the company with a flexible, reliable and responsive medical-isotope supplier of molybdenum-99 (Mo-99) for the global nuclear medicine
June 16, 2009
June 10, 2009 – MDS Nordion said today it commenced the manufacture of CardioGen-82 (rubidium Rb 82 generators) for Bracco Diagnostics Inc.
MDS Nordion has designed and built a dedicated manufacturing suite within its FDA-approved, Good Manufacturing Practices-compliant production facility in Ottawa. Production of CardioGen-82 began yesterday.
June 10, 2009
May 28, 2009 - MDS Nordion, a leading global provider of medical isotopes and radiopharmaceuticals used in molecular medicine, today announced the opening of a facility in Fleurus, Belgium for the production of Glucotrace (Fluorodeoxyglucose), a radiopharmaceutical used in positron emission tomography (PET) imaging.
May 28, 2009
March 5, 2009 – MDS Nordion, a leading provider of medical isotopes and radiopharmaceuticals, will showcase an improved administration system for TheraSphere, Yttrium-90 Microsphere (Y-90), a targeted internal radiation therapy for patients with inoperable, primary liver cancer, during the upcoming Society of Interventional Radiology 2009 (SIR 2009) scientific meeting in San Diego, CA.
March 11, 2009